Haemonetics Corporation (NYSE:HAE – Get Free Report) CAO Farris Maryanne Maunsell sold 836 shares of the firm’s stock in a transaction that occurred on Wednesday, November 11th. The stock was sold at an average price of $120.99, for a total value of $101,147.64. Following the sale, the chief accounting officer directly owned 5,828 shares of the company’s stock, valued at $705,129.72. This represents a 12.55% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link.
Haemonetics Stock Performance
HAE stock opened at $123.16 on Monday. Haemonetics Corporation has a twelve month low of $51.00 and a twelve month high of $132.00. The firm has a market cap of $5.61 billion, a price-to-earnings ratio of 55.23, a PEG ratio of 2.46 and a beta of 0.62. The business’s fifty day simple moving average is $113.34 and its two-hundred day simple moving average is $81.36. The company has a quick ratio of 1.83, a current ratio of 2.84 and a debt-to-equity ratio of 1.24.
Haemonetics (NYSE:HAE – Get Free Report) last announced its quarterly earnings data on Thursday, November 5th. The medical instruments supplier reported $1.35 earnings per share for the quarter, beating analysts’ consensus estimates of $1.29 by $0.06. The company had revenue of $357.76 million during the quarter, compared to analyst estimates of $345.15 million. Haemonetics had a net margin of 7.52% and a return on equity of 27.42%. The firm’s revenue for the quarter was up 9.4% on a year-over-year basis. During the same quarter last year, the business posted $1.27 EPS. Analysts predict that Haemonetics Corporation will post 5.32 earnings per share for the current year.
Analysts Set New Price Targets
A number of research analysts have commented on HAE shares. Barrington Research raised their target price on shares of Haemonetics from $140.00 to $145.00 and gave the company an “outperform” rating in a research report on Friday, November 6th. Robert W. Baird increased their target price on Haemonetics from $96.00 to $119.00 and gave the company an “outperform” rating in a research report on Friday, August 21st. JPMorgan Chase & Co. boosted their price target on Haemonetics from $62.00 to $86.00 and gave the stock a “neutral” rating in a research report on Friday, August 7th. Wall Street Zen cut Haemonetics from a “strong-buy” rating to a “buy” rating in a research note on Saturday, November 7th. Finally, Jefferies Financial Group began coverage on shares of Haemonetics in a report on Friday. They issued a “buy” rating and a $150.00 target price for the company. One research analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating and three have issued a Hold rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $129.00.
View Our Latest Research Report on Haemonetics
Institutional Investors Weigh In On Haemonetics
Large investors have recently modified their holdings of the business. Bank of America Corp DE purchased a new position in Haemonetics in the 2nd quarter valued at $33,326,000. Assenagon Asset Management S.A. raised its stake in shares of Haemonetics by 1,191.9% in the 3rd quarter. Assenagon Asset Management S.A. now owns 453,579 shares of the medical instruments supplier’s stock valued at $47,762,000 after acquiring an additional 418,470 shares during the period. William Blair Investment Management LLC acquired a new position in Haemonetics during the second quarter worth $24,906,000. Bank of New York Mellon Corp acquired a new position in Haemonetics during the 2nd quarter worth about $21,566,000. Finally, Dimensional Fund Advisors LP boosted its stake in shares of Haemonetics by 21.3% in the first quarter. Dimensional Fund Advisors LP now owns 1,326,057 shares of the medical instruments supplier’s stock valued at $74,731,000 after purchasing an additional 233,119 shares during the period. Hedge funds and other institutional investors own 99.67% of the company’s stock.
Haemonetics Company Profile
Haemonetics Corporation is a global medical technology company focused on blood and plasma collection, processing and management. Its products and services are used by plasma collection organizations, blood centers and hospitals. The company provides automated plasma collection systems and related software and supplies, as well as technologies for collecting and processing blood components. Its hospital offerings include devices for surgical blood salvage and tools that help clinicians assess blood clotting and guide transfusion decisions.
Read More
- Five stocks we like better than Haemonetics
- Intuitive Machines’ Business Is Taking Off—Will Its Stock Follow?
- The Next Big Thing May Not Be One Thing: Inside Lazard’s Megatrends ETF
- 3 Power and Grid Stocks That Could Keep Growing Even if AI Spending Slows
- Applied Materials Beats and Raises, But Investors Stay Unconvinced
Receive News & Ratings for Haemonetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Haemonetics and related companies with MarketBeat.com's FREE daily email newsletter.
